First and only oral therapy approved for mild, moderate, and severe plaque psoriasis, and active PsA SEE THE DATA

Plaque Psoriasis
3 INDICATIONS Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. Read more
*Estimates of patients treated reflect global data since launch (Apr 2014-Aug 2022; US=approximately 60% of data). Calculations based on observed drug utilization parameters and number of units distributed. Utilization patterns change over time to best represent current markets.
FDA, U.S. Food and Drug Administration; PsA, psoriatic arthritis; TB, tuberculosis.
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Otezla® (apremilast) FDA approval letter. March 21, 2014.
The safety profile for Otezla was studied in 6 clinical trials in both mild to moderate and moderate to severe plaque
psoriasis 2-4,†
*Moderate to severe plaque psoriasis patients in the ESTEEM clinical trials could be treated through 5 years. †The 6 clinical trials include ADVANCE, ESTEEM 1 & 2, STYLE, LIBERATE, and DISCREET.
‡Long-term exposure includes apremilast Phase 3 data pool in
the apremilast exposure period from week 0 through 5 years.
§Estimates of patients treated reflect global data since launch
(Apr 2014-Aug 2022; US=approximately 60% of data).
Calculations based on observed drug utilization parameters and number of units distributed. Utilization patterns change over time to best represent current markets.
The safety profile of Otezla in mild to moderate plaque psoriasis patients is consistent with the moderate to severe plaque psoriasis trials 2
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for the full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for
phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
References: 1. Data on file, Amgen Inc. 2. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 3. Reich K, Gooderham M, Green L, et al. J Eur Acad Dermatol Venereol. 2017;31(3):507-517. 4. Merola F, Parish L, Guenther L, et al. Abstract presented at: the 31st Annual Meeting of the European Academy of Dermatology and Venereology (EADV); September 7-10, 2022. 5. Otezla® (apremilast) FDA approval letter. March 21, 2014.